ALCL is a highly malignant lymphoma with a 5-year survival rate of 52%. It can be treated by radiotherapy, chemotherapy, bone marrow transplantation and cellular immunotherapy.
Chemotherapy is the most suitable, with complete remission (CR) in most cases, low recurrence rate and high 3-and 5-year survival rates.
Chemotherapy combined with CTC cell immunotherapy has the best effect and greatly improves the survival rate.
Radiotherapy has a good effect at first, but it is easy to recur in the long run.
Bone marrow transplantation is considered as an effective emergency treatment.
The cost of treatment is determined according to the treatment method.